Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAM133EP is classified as a human pseudogene, meaning it is a DNA sequence with high similarity to protein-coding genes but contains disabling mutations (such as premature stop codons or frameshifts) that prevent it from being translated into a functional protein[5][6]. Pseudogenes are generally considered nonfunctional remnants of ancestral genes; they do not encode active proteins, nor are they directly targeted by therapeutic drugs[6]. While some pseudogenes in the genome may play regulatory roles—such as acting as decoys for microRNA or affecting gene expression[1][2]—there is currently no evidence supporting any such function or disease relevance for FAM133EP specifically. It is listed in gene annotation databases with no assigned function, role in disease, or known pharmacological interactions[5][3]. Key points: - FAM133EP is not a receptor, enzyme, transporter, or any canonical drug target. - It is not associated with any known biological function, disease process, or drug interaction. - Its significance is limited to genomic annotation as a nonfunctional pseudogene. - Its inclusion as a therapeutic target is incorrect.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 133 member E, pseudogene (FAM133EP).